<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Cancer Studies</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9F1A9045-D181-4863-B49D-D0DA4670DA39"><gtr:id>9F1A9045-D181-4863-B49D-D0DA4670DA39</gtr:id><gtr:firstName>Eric</gtr:firstName><gtr:surname>So</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800892"><gtr:id>DFEEF446-7637-4A5D-967A-F6BE5A1A7F45</gtr:id><gtr:title>The roles of protein arginine methyltransferase, Prmt1 in hematopoiesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800892</gtr:grantReference><gtr:abstractText>Blood cells are responsible for many important functions, ranging from delivery of oxygen to killing of unwanted invaders in our body. Developmental defects in blood cell formation can result in various disease manifestations including anaemia, recurring infection and even cancers. In spite of its critical functions, we have very little knowledge about the regulation of blood cell development. The aim of this research is to study and characterize the role of a molecule, call Prmt1, in blood cell formation. Prmt1 is a protein with a specific enzymatic activity that regulates the expression of other genes, some of which are important for blood cell development. Prmt1 has also recently been implicated in leukemia, and inhibition of Prmt1 activity can specifically suppress a specific type of leukemia. However the function of Prmt1 in normal blood cell development in not clear, which limits the potential development and application of Prmt1 inhibitor in cancer. By characterizing the normal function of Prmt1, this research should give significant insights into underlying mechanisms for blood cell development, which will also provide useful information for future drug design that targets Prmt1.</gtr:abstractText><gtr:technicalSummary>Protein arginine methyltransferase I (Prmt1) is an important epigenetic modifier that mediates asymmetric dimethylation of arginine 3 of histone 4 (H4R3), a critical mark for transcriptional memory and maintenance of cellular identity during normal development. In leukemia, Prmt1 is hijacked by MLL fusion proteins for oncogenic transformation, which can be suppressed by specific knockdown of Prmt1 in transformed cells. Prmt1 also activates expression of genes,which are critical for normal hematopoiesis. While Prmt1 is an important molecule for transcription regulation and a potential therapeutic target in leukemia, its functions in normal development has not been defined. Thus the primary goal of this project is to characterize the roles of Prmt1 in normal hematopoietic development by both knockdown and conditional knockout mice approaches. The proposed research should define and give significant insights into the functions of Prmt1 in various stages of normal hematopoiesis (from hematopoietic stem cell to progenitors), which will also provide crucial information for current effort in developing specific inhibitors targeting Prmt1.</gtr:technicalSummary><gtr:fund><gtr:end>2014-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>443116</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press release</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4F5105AE-9CED-46D1-859B-D407D98BF57E</gtr:id><gtr:impact>In average, 5-10 nation and international agencies covered/distributed the press release related to our latest findings to the public.

Stimulated interests/inquiries from the public or professions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010,2011,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F4D0C328-B0D4-4E57-9867-C248A33D0D03"><gtr:id>F4D0C328-B0D4-4E57-9867-C248A33D0D03</gtr:id><gtr:title>Sox4you: a new player in C/EBPa leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dee8fba17c92fc7d05396a9834417201"><gtr:id>dee8fba17c92fc7d05396a9834417201</gtr:id><gtr:otherNames>Fung TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A848601-A7BF-4ECC-B0DA-E654C7293138"><gtr:id>9A848601-A7BF-4ECC-B0DA-E654C7293138</gtr:id><gtr:title>Mixed lineage leukemia protein in normal and leukemic stem cells.</gtr:title><gtr:parentPublicationTitle>Experimental biology and medicine (Maywood, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9527bfcbdb625e348951bfb95a09345f"><gtr:id>9527bfcbdb625e348951bfb95a09345f</gtr:id><gtr:otherNames>Yip BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-3699</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF921CAE-3FD6-4178-9284-19ED6DFE5F3E"><gtr:id>BF921CAE-3FD6-4178-9284-19ED6DFE5F3E</gtr:id><gtr:title>A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3633c2335831185bbc6e44665364dad"><gtr:id>c3633c2335831185bbc6e44665364dad</gtr:id><gtr:otherNames>Jiang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E8066D3-4631-487F-A4BE-E9B2922DF759"><gtr:id>7E8066D3-4631-487F-A4BE-E9B2922DF759</gtr:id><gtr:title>Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9eacb28e9921d908dae42d7b09175479"><gtr:id>9eacb28e9921d908dae42d7b09175479</gtr:id><gtr:otherNames>Smith LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31B6E7E7-9DE2-43B2-B3CF-4F4DB64A4DBD"><gtr:id>31B6E7E7-9DE2-43B2-B3CF-4F4DB64A4DBD</gtr:id><gtr:title>Leukemic transformation by the APL fusion protein PRKAR1A-RAR{alpha} critically depends on recruitment of RXR{alpha}.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/87ade5b3fea49a5fd2b1408460d61369"><gtr:id>87ade5b3fea49a5fd2b1408460d61369</gtr:id><gtr:otherNames>Qiu JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECF80E91-A125-40E8-AB58-90540A00B8E8"><gtr:id>ECF80E91-A125-40E8-AB58-90540A00B8E8</gtr:id><gtr:title>Linking MLL Leukemia with Integrin Signaling.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a190d3231983b2d77233049e0598cf4"><gtr:id>3a190d3231983b2d77233049e0598cf4</gtr:id><gtr:otherNames>Zeisig BB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE311092-1A5B-421C-B804-01758401F311"><gtr:id>BE311092-1A5B-421C-B804-01758401F311</gtr:id><gtr:title>Stem Cells and Cancer Stem Cells, Volume 10</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a272aa9fb5701af4221cc4480467ddfa"><gtr:id>a272aa9fb5701af4221cc4480467ddfa</gtr:id><gtr:otherNames>Fung T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB58E5BA-535B-42A2-860D-843FA63494AD"><gtr:id>EB58E5BA-535B-42A2-860D-843FA63494AD</gtr:id><gtr:title>Retroviral/Lentiviral transduction and transformation assay.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a190d3231983b2d77233049e0598cf4"><gtr:id>3a190d3231983b2d77233049e0598cf4</gtr:id><gtr:otherNames>Zeisig BB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F1267C8-6517-4A87-9B67-65263F5FAEE5"><gtr:id>6F1267C8-6517-4A87-9B67-65263F5FAEE5</gtr:id><gtr:title>Discovery of novel transcriptional and epigenetic targets in APL by global ChIP analyses: Emerging opportunity and challenge.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b6ef3af57f22a818d9f38ad62139b21"><gtr:id>0b6ef3af57f22a818d9f38ad62139b21</gtr:id><gtr:otherNames>Mikesch JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25E73AB9-0B7F-4BBB-B518-FAA95A4552E7"><gtr:id>25E73AB9-0B7F-4BBB-B518-FAA95A4552E7</gtr:id><gtr:title>SnapShot: Acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a190d3231983b2d77233049e0598cf4"><gtr:id>3a190d3231983b2d77233049e0598cf4</gtr:id><gtr:otherNames>Zeisig BB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40C74A12-905E-4808-9538-156DA82CF5DB"><gtr:id>40C74A12-905E-4808-9538-156DA82CF5DB</gtr:id><gtr:title>Interplay between Homeobox proteins and Polycomb repressive complexes in p16INK4a regulation.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2698db37f13851560a6e4e3aa5a78457"><gtr:id>2698db37f13851560a6e4e3aa5a78457</gtr:id><gtr:otherNames>Martin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6BEC7DF3-BD3D-4E81-8A85-059808EB8079"><gtr:id>6BEC7DF3-BD3D-4E81-8A85-059808EB8079</gtr:id><gtr:title>Identification and characterization of hematopoietic stem and progenitor cell populations in mouse bone marrow by flow cytometry.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9517aa25afd3be8aad87494e475bd7dc"><gtr:id>9517aa25afd3be8aad87494e475bd7dc</gtr:id><gtr:otherNames>Yeung J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0CC84C5-B895-4299-B2AD-9621E83DB50E"><gtr:id>B0CC84C5-B895-4299-B2AD-9621E83DB50E</gtr:id><gtr:title>Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3c0cff2c76afa8ed6f180d3f28953218"><gtr:id>3c0cff2c76afa8ed6f180d3f28953218</gtr:id><gtr:otherNames>Alvares CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41D5B043-7885-4FB1-B84C-8221DCB8FCF7"><gtr:id>41D5B043-7885-4FB1-B84C-8221DCB8FCF7</gtr:id><gtr:title>The role of CBFbeta in AML1-ETO's activity.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/178a15badbbc9aca443fa618c9138084"><gtr:id>178a15badbbc9aca443fa618c9138084</gtr:id><gtr:otherNames>Kwok C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A72250A0-B62C-433F-858B-D422446229F8"><gtr:id>A72250A0-B62C-433F-858B-D422446229F8</gtr:id><gtr:title>Transcriptional and epigenetic networks in haematological malignancy.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4fa79ed797e968c482d0ea306256e268"><gtr:id>4fa79ed797e968c482d0ea306256e268</gtr:id><gtr:otherNames>Cheung N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFAFD767-DA98-478F-A690-B209075A90ED"><gtr:id>DFAFD767-DA98-478F-A690-B209075A90ED</gtr:id><gtr:title>An overview: from discovery of candidate mutations to disease modeling and transformation mechanisms of acute leukemia.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/965fdaf84f571f6d6d9f235f6827619e"><gtr:id>965fdaf84f571f6d6d9f235f6827619e</gtr:id><gtr:otherNames>So CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6CADAF2C-2E9A-45D9-BE18-D6985F2543D1"><gtr:id>6CADAF2C-2E9A-45D9-BE18-D6985F2543D1</gtr:id><gtr:title>Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4fa79ed797e968c482d0ea306256e268"><gtr:id>4fa79ed797e968c482d0ea306256e268</gtr:id><gtr:otherNames>Cheung N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7072D752-83A6-4EEF-991B-3EA539F6D808"><gtr:id>7072D752-83A6-4EEF-991B-3EA539F6D808</gtr:id><gtr:title>Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44d78745142d16db9730afe4b03c9a49"><gtr:id>44d78745142d16db9730afe4b03c9a49</gtr:id><gtr:otherNames>Arteaga MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACE7328F-3DDA-40CF-9FE3-13D569497408"><gtr:id>ACE7328F-3DDA-40CF-9FE3-13D569497408</gtr:id><gtr:title>Overcoming treatment resistance in acute promyelocytic leukemia and beyond.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dee8fba17c92fc7d05396a9834417201"><gtr:id>dee8fba17c92fc7d05396a9834417201</gtr:id><gtr:otherNames>Fung TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6FA3D8C1-F7EA-4532-A87C-3799626BCDF0"><gtr:id>6FA3D8C1-F7EA-4532-A87C-3799626BCDF0</gtr:id><gtr:title>Collaboration between PcG proteins and MLL fusions in Leukemogenesis: an emerging paradigm.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a190d3231983b2d77233049e0598cf4"><gtr:id>3a190d3231983b2d77233049e0598cf4</gtr:id><gtr:otherNames>Zeisig BB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F7004345-1F6A-4900-B5E8-08F2B53E4818"><gtr:id>F7004345-1F6A-4900-B5E8-08F2B53E4818</gtr:id><gtr:title>A knockout Combo: eradicating AML Stem Cells with TKI plus SIRT1 inhibition.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a190d3231983b2d77233049e0598cf4"><gtr:id>3a190d3231983b2d77233049e0598cf4</gtr:id><gtr:otherNames>Zeisig BB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800892</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>